Synta Pharmaceuticals has garnered a $15 million payment from GlaxoSmithKline as part of its collaboration agreement for the cancer drug elesclomol. Elesclomol is in Phase III trials for metastatic melanoma and Phase I/II trials for prostate cancer. Synta stands to gain up to $585 million in pre-commercial milestone payments. Release